Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
53
FOLD Quote, Financials, Valuation and Earnings
Last price:
$9.96
Seasonality move
:
-1.54%
Day range:
$9.66 - $9.85
52-week range:
$5.51 - $10.57
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.00x
P/B ratio:
13.10x
Volume:
2.9M
Avg. volume:
5M
1-year change:
-0.1%
Market cap:
$3B
Revenue:
$528.3M
EPS (TTM):
-$0.04
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FOLD
Amicus Therapeutics, Inc.
|
$165.7M | $0.12 | 20.07% | 224.54% | $15.90 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$277.2M | $0.15 | 12.73% | -82.4% | $29.26 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$212.9M | $1.77 | 22% | 68.6% | $109.88 |
|
BEAM
Beam Therapeutics, Inc.
|
$12.7M | -$1.01 | -54.98% | -2.35% | $45.93 |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$136.8M | $0.54 | -0.23% | 4.65% | $34.86 |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FOLD
Amicus Therapeutics, Inc.
|
$9.78 | $15.90 | $3B | -- | $0.00 | 0% | 5.00x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$25.88 | $29.26 | $4.4B | 16.65x | $0.00 | 0% | 4.16x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$82.67 | $109.88 | $1.9B | 50.70x | $0.00 | 0% | 2.02x |
|
BEAM
Beam Therapeutics, Inc.
|
$26.74 | $45.93 | $2.7B | -- | $0.00 | 0% | 45.05x |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$23.10 | $34.86 | $2.8B | 13.48x | $0.00 | 0% | 5.07x |
|
CRMD
CorMedix, Inc.
|
$10.32 | $19.00 | $813.1M | 5.03x | $0.00 | 0% | 3.47x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | 0.379 | 18.22% | 1.91x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.330 | 1.52% | 2.70x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.550 | 30.7% | 2.40x |
|
BEAM
Beam Therapeutics, Inc.
|
13.55% | 2.089 | 6.16% | 5.89x |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
0.31% | -0.528 | 0.12% | 6.19x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
BEAM
Beam Therapeutics, Inc.
|
$4.1M | -$126.8M | -38.05% | -44.48% | -1307.6% | -$86.5M |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$116.4M | $66.3M | 27.37% | 27.48% | 44.66% | $32.4M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
Amicus Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns FOLD or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of 10.24% compared to Amicus Therapeutics, Inc.'s net margin of 25.76%. Amicus Therapeutics, Inc.'s return on equity of -7.02% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About FOLD or ACAD?
Amicus Therapeutics, Inc. has a consensus price target of $15.90, signalling upside risk potential of 62.58%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $29.26 which suggests that it could grow by 13.07%. Given that Amicus Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Amicus Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FOLDAmicus Therapeutics, Inc.6 1 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is FOLD or ACAD More Risky?
Amicus Therapeutics, Inc. has a beta of 0.463, which suggesting that the stock is 53.675% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.982%.
-
Which is a Better Dividend Stock FOLD or ACAD?
Amicus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FOLD or ACAD?
Amicus Therapeutics, Inc. quarterly revenues are $169.1M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Amicus Therapeutics, Inc.'s net income of $17.3M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Amicus Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 16.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics, Inc. is 5.00x versus 4.16x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FOLDAmicus Therapeutics, Inc.5.00x -- $169.1M $17.3M ACADACADIA Pharmaceuticals, Inc.4.16x 16.65x $278.6M $71.8M
-
Which has Higher Returns FOLD or ANIP?
ANI Pharmaceuticals, Inc. has a net margin of 10.24% compared to Amicus Therapeutics, Inc.'s net margin of 10.59%. Amicus Therapeutics, Inc.'s return on equity of -7.02% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.
Company Gross Margin Earnings Per Share Invested Capital FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B -
What do Analysts Say About FOLD or ANIP?
Amicus Therapeutics, Inc. has a consensus price target of $15.90, signalling upside risk potential of 62.58%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $109.88 which suggests that it could grow by 32.91%. Given that Amicus Therapeutics, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe Amicus Therapeutics, Inc. is more attractive than ANI Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FOLDAmicus Therapeutics, Inc.6 1 0 ANIPANI Pharmaceuticals, Inc.4 1 0 -
Is FOLD or ANIP More Risky?
Amicus Therapeutics, Inc. has a beta of 0.463, which suggesting that the stock is 53.675% less volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.639%.
-
Which is a Better Dividend Stock FOLD or ANIP?
Amicus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios FOLD or ANIP?
Amicus Therapeutics, Inc. quarterly revenues are $169.1M, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. Amicus Therapeutics, Inc.'s net income of $17.3M is lower than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, Amicus Therapeutics, Inc.'s price-to-earnings ratio is -- while ANI Pharmaceuticals, Inc.'s PE ratio is 50.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics, Inc. is 5.00x versus 2.02x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FOLDAmicus Therapeutics, Inc.5.00x -- $169.1M $17.3M ANIPANI Pharmaceuticals, Inc.2.02x 50.70x $227.8M $24.1M
-
Which has Higher Returns FOLD or BEAM?
Beam Therapeutics, Inc. has a net margin of 10.24% compared to Amicus Therapeutics, Inc.'s net margin of -1162.38%. Amicus Therapeutics, Inc.'s return on equity of -7.02% beat Beam Therapeutics, Inc.'s return on equity of -44.48%.
Company Gross Margin Earnings Per Share Invested Capital FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M BEAMBeam Therapeutics, Inc.42.67% -$1.10 $1.1B -
What do Analysts Say About FOLD or BEAM?
Amicus Therapeutics, Inc. has a consensus price target of $15.90, signalling upside risk potential of 62.58%. On the other hand Beam Therapeutics, Inc. has an analysts' consensus of $45.93 which suggests that it could grow by 71.76%. Given that Beam Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Beam Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FOLDAmicus Therapeutics, Inc.6 1 0 BEAMBeam Therapeutics, Inc.13 2 0 -
Is FOLD or BEAM More Risky?
Amicus Therapeutics, Inc. has a beta of 0.463, which suggesting that the stock is 53.675% less volatile than S&P 500. In comparison Beam Therapeutics, Inc. has a beta of 2.213, suggesting its more volatile than the S&P 500 by 121.346%.
-
Which is a Better Dividend Stock FOLD or BEAM?
Amicus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beam Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics, Inc. pays -- of its earnings as a dividend. Beam Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FOLD or BEAM?
Amicus Therapeutics, Inc. quarterly revenues are $169.1M, which are larger than Beam Therapeutics, Inc. quarterly revenues of $9.7M. Amicus Therapeutics, Inc.'s net income of $17.3M is higher than Beam Therapeutics, Inc.'s net income of -$112.7M. Notably, Amicus Therapeutics, Inc.'s price-to-earnings ratio is -- while Beam Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics, Inc. is 5.00x versus 45.05x for Beam Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FOLDAmicus Therapeutics, Inc.5.00x -- $169.1M $17.3M BEAMBeam Therapeutics, Inc.45.05x -- $9.7M -$112.7M
-
Which has Higher Returns FOLD or CPRX?
Catalyst Pharmaceuticals, Inc. has a net margin of 10.24% compared to Amicus Therapeutics, Inc.'s net margin of 35.57%. Amicus Therapeutics, Inc.'s return on equity of -7.02% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48%.
Company Gross Margin Earnings Per Share Invested Capital FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M CPRXCatalyst Pharmaceuticals, Inc.78.44% $0.42 $923.1M -
What do Analysts Say About FOLD or CPRX?
Amicus Therapeutics, Inc. has a consensus price target of $15.90, signalling upside risk potential of 62.58%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.86 which suggests that it could grow by 50.9%. Given that Amicus Therapeutics, Inc. has higher upside potential than Catalyst Pharmaceuticals, Inc., analysts believe Amicus Therapeutics, Inc. is more attractive than Catalyst Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FOLDAmicus Therapeutics, Inc.6 1 0 CPRXCatalyst Pharmaceuticals, Inc.6 0 0 -
Is FOLD or CPRX More Risky?
Amicus Therapeutics, Inc. has a beta of 0.463, which suggesting that the stock is 53.675% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.5%.
-
Which is a Better Dividend Stock FOLD or CPRX?
Amicus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FOLD or CPRX?
Amicus Therapeutics, Inc. quarterly revenues are $169.1M, which are larger than Catalyst Pharmaceuticals, Inc. quarterly revenues of $148.4M. Amicus Therapeutics, Inc.'s net income of $17.3M is lower than Catalyst Pharmaceuticals, Inc.'s net income of $52.8M. Notably, Amicus Therapeutics, Inc.'s price-to-earnings ratio is -- while Catalyst Pharmaceuticals, Inc.'s PE ratio is 13.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics, Inc. is 5.00x versus 5.07x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FOLDAmicus Therapeutics, Inc.5.00x -- $169.1M $17.3M CPRXCatalyst Pharmaceuticals, Inc.5.07x 13.48x $148.4M $52.8M
-
Which has Higher Returns FOLD or CRMD?
CorMedix, Inc. has a net margin of 10.24% compared to Amicus Therapeutics, Inc.'s net margin of 49.9%. Amicus Therapeutics, Inc.'s return on equity of -7.02% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About FOLD or CRMD?
Amicus Therapeutics, Inc. has a consensus price target of $15.90, signalling upside risk potential of 62.58%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 84.11%. Given that CorMedix, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe CorMedix, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FOLDAmicus Therapeutics, Inc.6 1 0 CRMDCorMedix, Inc.4 0 0 -
Is FOLD or CRMD More Risky?
Amicus Therapeutics, Inc. has a beta of 0.463, which suggesting that the stock is 53.675% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock FOLD or CRMD?
Amicus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FOLD or CRMD?
Amicus Therapeutics, Inc. quarterly revenues are $169.1M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Amicus Therapeutics, Inc.'s net income of $17.3M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Amicus Therapeutics, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 5.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics, Inc. is 5.00x versus 3.47x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FOLDAmicus Therapeutics, Inc.5.00x -- $169.1M $17.3M CRMDCorMedix, Inc.3.47x 5.03x $104.3M $108.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
